Needham Reiterates Buy on Mereo BioPharma Group, Maintains $5 Price Target
Benzinga Newsdesk 10 months ago
NewsPrice TargetReiterationAnalyst Ratings
Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $5 price target.
Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $5 price target.